Apuli Maricel 4
4 · BridgeBio Pharma, Inc. · Filed Feb 18, 2026
Research Summary
AI-generated summary of this filing
BridgeBio (BBIO) CAO Apuli Maricel Sells Shares
What Happened
Apuli Maricel, Chief Accounting Officer of BridgeBio (BBIO), disposed of a total of 4,859 shares in two transactions. On 2026-02-16, 4,349 shares were withheld to satisfy tax obligations related to the vesting of RSUs (withheld at $75.25/share, value $327,262). On 2026-02-17, she sold 510 shares in the open market at $74.31/share for $37,898. Total proceeds/values of the two dispositions are approximately $365,160. These were dispositions (sales/tax withholding), not purchases.
Key Details
- Transaction dates and prices:
- 2026-02-16: 4,349 shares withheld for taxes at $75.25 — $327,262 (code F: tax withholding).
- 2026-02-17: 510 shares sold open market at $74.31 — $37,898 (code S).
- Shares owned after transaction: Not disclosed in this filing.
- Footnotes of note:
- F1: 4,349 shares were withheld to satisfy taxes on the vesting of 8,377 RSUs.
- F2: The 510 shares sold include shares acquired Feb 13, 2026 via the company ESPP (exempt under Rule 16b‑3).
- F3: The Feb 17 sale was effected under a Rule 10b5‑1 trading plan adopted Sept 8, 2025.
- Filing timeliness: Report filed 2026-02-18 for transactions on 2026-02-16 and 2026-02-17 — appears timely under Form 4 rules.
Context
Tax-withholding dispositions are a common cashless way to cover tax on vested RSUs and do not necessarily reflect a view on the company’s prospects. The open-market sale was executed under a pre-established 10b5‑1 plan, which typically schedules trades in advance. Purchases are generally more informative about insider sentiment; these transactions are routine dispositions and should be interpreted accordingly.
Insider Transaction Report
- Tax Payment
Common Stock
[F1][F2]2026-02-16$75.25/sh−4,349$327,262→ 124,455 total - Sale
Common Stock
[F3]2026-02-17$74.31/sh−510$37,898→ 123,945 total
Footnotes (3)
- [F1]Represents number of shares of the Issuer's Common Stock withheld to satisfy the Reporting Person's tax obligation in connection with the vesting of 8,377 shares of Common Stock underlying the Reporting Person's RSUs.
- [F2]Includes 510 shares of the Issuer's Common Stock acquired by the Reporting Person on February 13, 2026 pursuant to the Issuer's Employee Stock Purchase Plan in a transaction exempt under Rule 16b-3.
- [F3]This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on September 8, 2025.